Clinical and Translational Allergy最新文献

{"title":"Why Is the Prevention of Passive Transport of Cat Allergens So Important in Clinical Practice?","authors":"Gennaro Liccardi, Matteo Martini, Maria Beatrice Bilò, Lorenzo Cecchi, Manlio Milanese, Roberta Maniscalco, Paola Rogliani","doi":"10.1002/clt2.70197","DOIUrl":"https://doi.org/10.1002/clt2.70197","url":null,"abstract":"<p>To the Editor</p><p>We read with interest the article of Colosimo et al. [<span>1</span>] concerning innovative strategies to reduce exposure and consequent allergic sensitization to cat allergen Fel d 1.</p><p>The article is very complete, and we have no objections to its contents. However, we wish to address an additional and universal exposure pathway that is the passive transport of cat allergens in animal-free environments and, above all, the lack of information on preventive measures to this crucial aspect.</p><p>This clarification is important because the majority of the innovative strategies reported in the text are applicable just to the single cat that is owned by the patient, or to the indoor environment where the animal lives. Obviously, patients remain exposed to the allergens/environments of other cats that they may encounter. On the contrary, targeted prevention measures against passive transport have a universal character as they should reduce the phenomenon of the “ubiquity” of the cat allergen and therefore the risk of sensitization without contact with animals.</p><p>Cat (and dog) allergens should be considered as ubiquitous because they are found not only in indoor environments where these animals are kept, but also in other indoor private or public places where they have never been kept. Public spaces include nurseries, offices, hospitals, hotels, schools and means of public transport. These indoor environments, contaminated by cat allergens, are able to induce allergic sensitization in susceptible individuals and trigger respiratory symptoms in already highly sensitized subjects. In fact, in these contaminated environments, the amount of cat allergens is higher than clinically significant thresholds. Namely, 1 and 8–10 μg of allergen/g are generally recognized as sufficient to induce sensitization or trigger respiratory symptoms for dust, respectively. Obviously, these thresholds must be considered as “averages” over the population examined in clinical studies. However, in clinical practice, it is necessary to account the wide individual susceptibility to pet allergen exposure resulting from genetic and environmental factors, as these variables are able of influencing the onset of more or less severe symptoms.</p><p>In developed countries, the cat allergen ubiquity causes a persistent stimulation of airways like that induced by dust mite.</p><p>Accumulation of cat allergens in indoor environments without animals is correlated with the number of visitors owning a cat or with those who are in regular contact with these animals. We have shown that clothing [<span>2</span>], but also human hair [<span>3</span>], constitute a means of transferring cat allergens into pet-free indoor environments (Figure 1).</p><p>We have previously demonstrated it in a less common pet (rabbit) [<span>5</span>]. However, a smaller body of evidence suggests the possibility of passive transport of allergens also in other animals such as horses [<s","PeriodicalId":10334,"journal":{"name":"Clinical and Translational Allergy","volume":"16 9","pages":""},"PeriodicalIF":4.2,"publicationDate":"2026-09-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/clt2.70197","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148872064","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"ARIA-EAACI 2025: Person-Centred, Digitally Enabled and Artificial Intelligence-Assisted Change Management in Airway Diseases","authors":"Jean Bousquet,&nbsp;Bernardo Sousa-Pinto,&nbsp;Mohamed H. Shamji,&nbsp;Maria J. Torres,&nbsp;Ludger Klimek,&nbsp;Holger J. Schünemann,&nbsp;Mario Morais-Almeida,&nbsp;Rafael José Vieira,&nbsp;Alkis Togias,&nbsp;Boleslaw Samolinski,&nbsp;Arunas Valiulis,&nbsp;Siân Williams,&nbsp;Oliver Pfaar,&nbsp;Torsten Zuberbier,&nbsp;Anna Bedbrook,&nbsp;Wienczyslawa Czarlewski,&nbsp;Maryam Ali Al-Nesf,&nbsp;Rita Amaral,&nbsp;Josep M. Anto,&nbsp;Antonio Bognanni,&nbsp;Luisa Brussino,&nbsp;Alvaro A. Cruz,&nbsp;Violeta Kvedariene,&nbsp;Habib Douagui,&nbsp;Nikolaos G. Papadopoulos,&nbsp;G. Walter Canonica,&nbsp;Ivan Cherrez-Ojeda,&nbsp;Mark Dykewicz,&nbsp;Bilun Gemicioglu,&nbsp;Mattia Giovannini,&nbsp;Brigita Gradauskiene,&nbsp;Tari Haahtela,&nbsp;Cristina Jacomelli,&nbsp;Tuomas Jartti,&nbsp;Miloš Jeseňák,&nbsp;Piotr Kuna,&nbsp;Désirée E. Larenas-Linnemann,&nbsp;Amir H. A. Latiff,&nbsp;Bryan Martin,&nbsp;Yousser Mohammad,&nbsp;Kari Nadeau,&nbsp;Elizabete Nunes,&nbsp;Ken Ohta,&nbsp;Martial Ouédraogo,&nbsp;Padukudru A. Mahesh,&nbsp;Isabella Pali-Schölll,&nbsp;Ana Margarida Pereira,&nbsp;Frederico S. Regateiro,&nbsp;Nicolas Roche,&nbsp;Mikhail Sofiev,&nbsp;Luis Taborda-Barata,&nbsp;Charlotte Suppli Ulrik,&nbsp;Sanna K. Toppila-Salmi,&nbsp;Marylin Valentin Rostan,&nbsp;Leticia de las Vecillas,&nbsp;Maria Teresa Ventura,&nbsp;Giovanni Viegi,&nbsp;De Yun Wang,&nbsp;He Zhang,&nbsp;Luo Zhang,&nbsp;Giorgio Ciprandi,&nbsp;Juan Carlos Ivancevich,&nbsp;Nikolai Khaltaev,&nbsp;Olga Lourenço,&nbsp;Lucas Leemann,&nbsp;Marine Savouré,&nbsp;Juan Jose Yepes-Nuñez,&nbsp;Arzu Yorgancioglu,&nbsp;Baharudin Abdullah,&nbsp;Mona Al-Ahmad,&nbsp;Julijana Asllani,&nbsp;Karl-C. Bergmann,&nbsp;Jonathan A. Bernstein,&nbsp;Michael S. Blaiss,&nbsp;Fulvio Braido,&nbsp;Pedro Carreiro-Martins,&nbsp;Lorenzo Cecchi,&nbsp;Antonio F. M. Giuliano,&nbsp;George Christoff,&nbsp;Ieva Cirule,&nbsp;Jaime Correia-de-Sousa,&nbsp;Elisio M. Costa,&nbsp;Biljana Cvetkovski,&nbsp;Stefano Del Giacco,&nbsp;Philippe Devillier,&nbsp;Dejan Dokic,&nbsp;Maia Gotua,&nbsp;Maria Antonieta Guzman,&nbsp;Elham Hossny,&nbsp;Tomohisa Iinuma,&nbsp;Carla Irani,&nbsp;Zhanat Ispayeva,&nbsp;Kaja Julge,&nbsp;Igor Kaidashev,&nbsp;Kazi S. Bennoor,&nbsp;Helga Kraxner,&nbsp;Inger Kull,&nbsp;Marek Kulus,&nbsp;Maciej Kupczyk,&nbsp;Andriy Kurchenko,&nbsp;Xin Luo,&nbsp;Stefania La Grutta,&nbsp;Lan Le Thi Tuyet,&nbsp;Michael Makris,&nbsp;Branislava Milenkovic,&nbsp;Neven Miculinic,&nbsp;Sang Min Lee,&nbsp;Stephen Montefort,&nbsp;André Moreira,&nbsp;Joaquim Mullol,&nbsp;Rachel Nadif,&nbsp;Alla Nakonechna,&nbsp;Hugo E. Neffen,&nbsp;Stefania Nicola,&nbsp;Marek Niedoszytko,&nbsp;Dieudonné Nyembue,&nbsp;Robyn E. O’Hehir,&nbsp;Ismail Ogulur,&nbsp;Yoshitaka Okamoto,&nbsp;Markus Ollert,&nbsp;Heidi Olze,&nbsp;Oscar Palomares,&nbsp;Petr Panzner,&nbsp;Hae-Sim Park,&nbsp;Vincenzo Patella,&nbsp;Ruby Pawankar,&nbsp;Constantinos Pitsios,&nbsp;Todor A. Popov,&nbsp;Francesca Puggioni,&nbsp;Santiago Quirce,&nbsp;Agné Ramonaité,&nbsp;Marysia Recto,&nbsp;Maria Susana Repka-Ramirez,&nbsp;Karla Robles-Velasco,&nbsp;Menachem Rottem,&nbsp;Marianella Salapatas,&nbsp;Joaquin Sastre,&nbsp;Nicola Scichilone,&nbsp;Juan-Carlos Sisul,&nbsp;Dirceu Solé,&nbsp;Manuel Soto-Martinez,&nbsp;Milan Sova,&nbsp;Katarina Stevanovic,&nbsp;Pongsakorn Tantilipikorn,&nbsp;Ana Todo-Bom,&nbsp;Vladyslav Tsaryk,&nbsp;Ioanna Tsiligianni,&nbsp;Marilyn Urrutia-Pereira,&nbsp;Erkka Valovirta,&nbsp;Tuula Vasankari,&nbsp;Dana Wallace,&nbsp;Margitta Worm,&nbsp;Osman M. Yusuf,&nbsp;Fares Zaitoun,&nbsp;Mihaela Zidarn,&nbsp;ARIA study group","doi":"10.1002/clt2.70192","DOIUrl":"https://doi.org/10.1002/clt2.70192","url":null,"abstract":"<p>Allergic Rhinitis and its Impact on Asthma (ARIA) was, up until 2017, a guideline using the best evidence (Grading of Recommendations, Assessment, Development and Evaluation, GRADE) and developed as a change management strategy. A second change management strategy—in collaboration with the European Academy of Allergy and Clinical Immunology (ARIA-EAACI)—was developed as a person-centred, digitally enabled, artificial intelligence-assisted care (person-centred care) with strong political involvement. The digital tools of ARIA are mainly based on MASK-air, an Organisation for Economic Co-operation and Development (OECD) Best Practice for integrated care for chronic diseases. Artificial intelligence was used, in particular, to approach the patients' views and expectations. The current paper describes the steps to build and achieve a new change management strategy. The future of the Change Management strategy is (i) a collaboration between ARIA and EAACI, (ii) the development of ARIA 2024-2025 guidelines, (iii) the new ARIA-MeDALL classification of multimorbid airway diseases and (iv) embedding MASK-air in a registry for severe allergic diseases. The ultimate goals of the ARIA-EAACI change management strategy will be (i) the transformation of health and care in rhinitis and asthma multimorbidity and (ii) the development of novel guidelines and policies in a cost-effective manner, improving shared-decision-making.</p>","PeriodicalId":10334,"journal":{"name":"Clinical and Translational Allergy","volume":"16 8","pages":""},"PeriodicalIF":4.2,"publicationDate":"2026-08-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/clt2.70192","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148783945","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Berotralstat Tolerability and Effectiveness in Hereditary Angioedema: Berolife Study Results","authors":"Delphine Gobert,&nbsp;David Launay,&nbsp;Isabelle Boccon-Gibod,&nbsp;Melisande Bourgoin-Heck,&nbsp;Cyrille Hoarau,&nbsp;Yann Ollivier,&nbsp;Hervé Maillard,&nbsp;Fabien Pontille,&nbsp;Nicolas Ozanne,&nbsp;Magali Aubineau,&nbsp;Claire de Moreuil,&nbsp;Anne Gerber,&nbsp;Fabien Pelletier,&nbsp;Pierre-Yves Jeandel,&nbsp;Aurélie Du-Thanh,&nbsp;Marie-Caroline Dalmas,&nbsp;Marie-Caroline Taquet,&nbsp;Jean Schmidt,&nbsp;Amélie Servettaz,&nbsp;Amandine Perier,&nbsp;Enzo Cohen,&nbsp;Laure Carriat,&nbsp;Nicolas Lemaire,&nbsp;Mona Villedieu,&nbsp;Jean-Charles Crave,&nbsp;Olivier Fain,&nbsp;Laurence Bouillet","doi":"10.1002/clt2.70193","DOIUrl":"10.1002/clt2.70193","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Berotralstat is a first-line once-daily oral prophylactic treatment for hereditary angioedema (HAE). Berolife was designed to evaluate the tolerability and effectiveness of berotralstat in real-world conditions.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>Berolife is an open-label, multicenter, observational study conducted in France from September 2021 to January 2024. The primary objective was to assess tolerability, and secondary objectives included characterization of the treated population and assessment of berotralstat effectiveness. HAE attack rate was assessed before and after initiation of berotralstat using the paired Wilcoxon rank-sum test.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Altogether, 80 patients were enrolled in the study (75 with HAE-C1INH type 1 or 2 and 5 with HAE-nC1INH) and received at least one dose of berotralstat. At baseline, patients had a mean (standard deviation [SD]) age of 40.0 (17.5) years, and most (67.5%) had received prior long-term prophylaxis treatment. The mean (SD) duration of berotralstat treatment was 11.5 (8.5) months. Treatment-related adverse events (AEs) occurred in 45.0% of patients, with gastrointestinal disorders being the most common (diarrhea: 13.8%, abdominal pain: 12.5%, upper abdominal pain: 7.5%). Importantly, no treatment-related serious AEs were reported. A total of 61 patients were treated with berotralstat for ≥ 6 months and evaluated for effectiveness. At 6 months of treatment, a significant reduction in monthly HAE attack rates was observed (mean [SD]: 0.62 [0.66] vs. mean [SD]: 1.25 [1.10] at baseline; <i>p</i> = 0.001).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>Berotralstat was generally well tolerated with a tolerability profile consistent with prior clinical trials. Significant reductions in monthly HAE attack rates were observed, confirming its effectiveness in real-world settings.</p>\u0000 </section>\u0000 </div>","PeriodicalId":10334,"journal":{"name":"Clinical and Translational Allergy","volume":"16 8","pages":""},"PeriodicalIF":4.2,"publicationDate":"2026-08-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13477265/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148758807","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"New Insights Into Immunomodulatory Strategies for Drug Hypersensitivity Reactions: An EAACI Task Force Report","authors":"Ana Maria Copaescu,&nbsp;Valentina Gueli,&nbsp;Jitesh Chahuan,&nbsp;Waad Albalawi,&nbsp;Giovanna Sfriso,&nbsp;Mattia Giovannini,&nbsp;Leticia de las Vecillas,&nbsp;Aspasia Karavelia,&nbsp;Marina Labella,&nbsp;Ruben Fernandez-Santamaria,&nbsp;Francesca Mori,&nbsp;Lene H. Garvey,&nbsp;Patrizia Bonadonna,&nbsp;Maria Jose Torres","doi":"10.1002/clt2.70195","DOIUrl":"https://doi.org/10.1002/clt2.70195","url":null,"abstract":"<p>Drug hypersensitivity reactions (DHRs) are a global health concern and remain challenging to investigate owing to the heterogeneity of endotypes and phenotypes, as well as the lack of standardized biomarkers. Until recently, strict drug avoidance was the only management strategy for severe DHRs. However, the development of novel therapeutic options, including biologics and drug desensitization protocols, has shown promising results, particularly when no alternatives exist. In parallel, the search for reliable biomarkers for diagnosis and monitoring immunomodulatory strategies is essential to improve patient care. Advances in the algorithms and digital tools also offer opportunities for enhanced risk stratification and more efficient delabeling of patients who may be incorrectly classified as allergic. In this review, we summarize recent advances in the classification of DHRs, discuss current and emerging immunomodulatory strategies for their management, and highlight relevant biomarkers, emphasizing the need to integrate them into clinical practice.</p>","PeriodicalId":10334,"journal":{"name":"Clinical and Translational Allergy","volume":"16 8","pages":""},"PeriodicalIF":4.2,"publicationDate":"2026-08-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/clt2.70195","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148753453","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Steroid Sparing Effect of 300IR House Dust Mite Sublingual Immunotherapy Tablet in Mite Allergic Rhinitis","authors":"Oliver Pfaar,&nbsp;Pascal Demoly,&nbsp;Philippe Gevaert,&nbsp;Ludger Klimek,&nbsp;Carmen Vidal,&nbsp;Margitta Worm,&nbsp;Randolf Brehler,&nbsp;Thomas B. Casale,&nbsp;Giorgio Walter Canonica","doi":"10.1002/clt2.70185","DOIUrl":"10.1002/clt2.70185","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>In a large randomized controlled trial (NCT02443805) in moderate-to-severe house dust mite (HDM) allergic rhinitis (AR) patients with/without controlled asthma, the 300IR HDM sublingual immunotherapy (SLIT) tablet confirmed its efficacy in reducing symptoms and rescue medication (RM) use. This post hoc analysis aimed at assessing the potential steroid sparing effect of this tablet.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>Participants receiving 300IR HDM SLIT-tablet or placebo for ∼12 months could use antihistamines (AH1), corticosteroids (CS – intranasal (INCS), or oral (OCS)) in a stepwise manner for subjective intolerable nasal/ocular symptoms. The proportions of patients and days with RM intake (overall and by drug class) were assessed over time and compared between groups (Chi-squared or Wilcoxon rank-sum tests). An odds that is, ratio of probability of using CS/probability of not using CS was calculated. Mean weekly CS doses were analyzed by ANCOVA.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Of 1262 evaluable patients, ∼60% used at least one CS at baseline: 300IR = 373 and placebo = 396. During treatment, the proportions of patients using RM, oral AH1, and CS and of days with RM use decreased in both groups, systematically in favor of 300IR (<i>p</i> &lt; 0.05 at end-of-treatment). Odds results indicated SLIT-patients were more likely not to use CS, whereas placebo-patients were more likely to use CS (<i>p</i> &lt; 0.05 at end-of-treatment). After 12 months, 54% SLIT-patients were able to discontinue CS completely versus 42% placebo-patients (<i>p</i> = 0.0007). Those who were still using CS were taking fewer and lower doses than placebo-patients.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>In moderate to severe HDM-AR patients, the 300IR HDM SLIT-tablet showed a steroid sparing effect.</p>\u0000 </section>\u0000 </div>","PeriodicalId":10334,"journal":{"name":"Clinical and Translational Allergy","volume":"16 8","pages":""},"PeriodicalIF":4.2,"publicationDate":"2026-08-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/clt2.70185","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148711554","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Birch Rust Spore Exposure and Upper Airway Symptom Dynamics in a Subarctic Region: Indications for a Novel Seasonal Allergen","authors":"Randi Falnes Olsen,&nbsp;Kristian Svendsen,&nbsp;Thorsten Graf,&nbsp;Annette Kuehn,&nbsp;Viera Stubnova,&nbsp;Martin Sørensen","doi":"10.1002/clt2.70196","DOIUrl":"10.1002/clt2.70196","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Airway allergies affect 20%–30% of the global population, with pollen and fungal spores representing major environmental triggers. Although fungal spores are far more abundant than pollen, their allergenic role—particularly from phytopathogenic rust fungi such as birch rust (BR)—remains poorly understood. In Northern Norway, where seasonal dispersal of BR spores occurs with minimal overlap from other aeroallergen exposures, we investigated their potential contribution to autumnal airway symptoms by linking spore distribution with clinical outcomes.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>In this prospective study, 160 patients and 94 controls were followed during BR season (Aug-Oct) and out of season (Jan-Feb). Participants reported allergic rhinitis, conjunctivitis, and/or asthma. Symptom scores (Visual Analogue Scale), nasal airflow (Peak Nasal Inspiratory Flow), and lung function (spirometry) were recorded, alongside daily BR spore counts from three monitoring sites.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>During BR season, patients showed significantly higher symptom severity (VAS difference 1.58, <i>p</i> &lt; 0.01) and lower PNIF values (−12.2 L/min, <i>p</i> = 0.01) versus controls. Seasonal increases in symptoms were observed (1.70, <i>p</i> &lt; 0.001), and anti-allergic medication use was more frequent in patients (62.5% of patients vs. 1.1% of controls (<i>p</i> &lt; 0.001). Symptom worsening was associated with reported proximity to birch forests (regression coefficient 0.46, <i>p</i> &lt; 0.01, <i>R</i>² = 0.48).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>BR spore exposure was associated with increased autumnal airway symptoms, suggesting that BR may represent an underrecognized trigger. These findings highlight the need for further research, including allergen-specific testing and dispersal modelling, to clarify their clinical relevance.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Trial Registration</h3>\u0000 \u0000 <p>This study is registered at ClinicalTrials.gov (identifier: NCT05661812)</p>\u0000 </section>\u0000 </div>","PeriodicalId":10334,"journal":{"name":"Clinical and Translational Allergy","volume":"16 8","pages":""},"PeriodicalIF":4.2,"publicationDate":"2026-08-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13454375/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148700974","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Dupilumab Combined With House Dust Mite Allergen Immunotherapy for Atopic Dermatitis: A Systematic Review and Meta-Analysis","authors":"Jiale Lian,&nbsp;Ling Ren,&nbsp;Jing Liang,&nbsp;Shuping Guo","doi":"10.1002/clt2.70194","DOIUrl":"10.1002/clt2.70194","url":null,"abstract":"&lt;div&gt;\u0000 \u0000 \u0000 &lt;section&gt;\u0000 \u0000 &lt;h3&gt; Background&lt;/h3&gt;\u0000 \u0000 &lt;p&gt;Dupilumab is effective for moderate-to-severe atopic dermatitis (AD), but sustained disease control after treatment discontinuation remains challenging. House dust mite allergen immunotherapy (HDM-AIT) may provide disease-modifying effects in sensitized patients, but the added value of combining HDM-AIT with dupilumab remains unclear.&lt;/p&gt;\u0000 &lt;/section&gt;\u0000 \u0000 &lt;section&gt;\u0000 \u0000 &lt;h3&gt; Objective&lt;/h3&gt;\u0000 \u0000 &lt;p&gt;To evaluate the efficacy and safety of dupilumab combined with HDM-AIT versus dupilumab monotherapy in patients with AD.&lt;/p&gt;\u0000 &lt;/section&gt;\u0000 \u0000 &lt;section&gt;\u0000 \u0000 &lt;h3&gt; Methods&lt;/h3&gt;\u0000 \u0000 &lt;p&gt;PubMed, Embase, Web of Science, and Cochrane Library were searched from inception to April 21, 2026. Randomized controlled trials and comparative observational studies evaluating dupilumab plus HDM-AIT versus dupilumab alone were included. Disease severity assessed by EASI or SCORAD was pooled using standardized mean differences (SMDs), Dermatology Life Quality Index (DLQI) using mean differences, and adverse events using risk ratios. Random-effects models were applied. The certainty of evidence was assessed using the GRADE approach.&lt;/p&gt;\u0000 &lt;/section&gt;\u0000 \u0000 &lt;section&gt;\u0000 \u0000 &lt;h3&gt; Results&lt;/h3&gt;\u0000 \u0000 &lt;p&gt;Four studies involving 138 patients were included, comprising one randomized controlled trial and three comparative observational studies. Combination therapy showed no significant improvement in disease severity at 6 months (SMD = −0.02, 95% CI −0.41 to 0.36; &lt;i&gt;I&lt;/i&gt;&lt;sup&gt;2&lt;/sup&gt; = 0%) or 12 months (SMD = 0.53, 95% CI −1.10 to 2.16; &lt;i&gt;I&lt;/i&gt;&lt;sup&gt;2&lt;/sup&gt; = 93%). At 18 months, the pooled estimate suggested a possible benefit of combination therapy for disease severity, although the certainty of evidence was very low (SMD = −0.96, 95% CI −1.76 to −0.17; &lt;i&gt;I&lt;/i&gt;&lt;sup&gt;2&lt;/sup&gt; = 61%), although evidence was limited. At the follow-up closest to 30 months, the effect favored combination therapy but was not significant (SMD = −1.16, 95% CI −2.56 to 0.24; &lt;i&gt;I&lt;/i&gt;&lt;sup&gt;2&lt;/sup&gt; = 87%). No significant differences were observed in DLQI, overall adverse events, or ocular adverse events.&lt;/p&gt;\u0000 &lt;/section&gt;\u0000 \u0000 &lt;section&gt;\u0000 \u0000 &lt;h3&gt; Conclusion&lt;/h3&gt;\u0000 \u0000 &lt;p&gt;Current evidence regarding dupilumab combined with HDM-AIT for AD remains limited and inconclusive. Although an exploratory signal of improved disease severity was observed at 18 months, the available data did not demonstrate a statistically significant difference in adverse events, and the certainty of evidence was very low for all evaluated outcomes. Further adequately powere","PeriodicalId":10334,"journal":{"name":"Clinical and Translational Allergy","volume":"16 8","pages":""},"PeriodicalIF":4.2,"publicationDate":"2026-08-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13452629/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148697101","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Sustained Effectiveness of Lanadelumab in Preventing Hereditary Angioedema Attacks: The ENABLE Study","authors":"Andrea Zanichelli,&nbsp;Walter A. Wuillemin,&nbsp;Markus Magerl,&nbsp;Andreas Recke,&nbsp;Mauro Cancian,&nbsp;Emel Aygören-Pürsün,&nbsp;Ramón Lleonart Bellfill,&nbsp;Aharon Kessel,&nbsp;Tamar Kinaciyan,&nbsp;Robin Lochbaum,&nbsp;Mona Al-Ahmad,&nbsp;Irmgard Andresen,&nbsp;Maureen Watt,&nbsp;Natalie Khutoryansky,&nbsp;Daniel N. Castaner,&nbsp;Inmaculada Martinez-Saguer","doi":"10.1002/clt2.70190","DOIUrl":"10.1002/clt2.70190","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Lanadelumab has been approved for hereditary angioedema (HAE) long-term prophylaxis since 2018. The Phase 4, prospective ENABLE Study (NCT04130191) evaluated the long-term effectiveness and safety of lanadelumab in clinical practice across Europe and the Middle East.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>Patients with HAE aged ≥ 12 years initiating lanadelumab treatment (300 mg every 2 weeks) per approved product labeling were recruited from Austria, Germany, Israel, Italy, Kuwait, Spain, and Switzerland and followed for up to 36 months (± 30 days). The primary objective was to evaluate lanadelumab effectiveness for HAE attack prevention. Safety and patient-reported health-related quality of life (HRQoL) were also evaluated.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Outcomes were analyzed in 138 patients (mean [range] age: 41.0 [14–79] years; 62.3% female; 92.0% HAE-C1INH-Type1), of whom &gt; 60% extended dosing intervals by Month 12. Over a mean ± SD treatment duration of 28.6 ± 9.8 months, mean ± SD patient-reported HAE attack rate decreased from 3.88 ± 3.43 attacks/month pre-lanadelumab to 0.30 ± 0.53 attacks/month (mean decrease, 84% [median 96%]). The incidence-rate ratio was 0.07 (95% CI: 0.06–0.10), reflecting a 93% reduction from modeled pre-lanadelumab rates. Overall, 95/138 patients reported treatment-emergent adverse events (TEAEs); most were unrelated to lanadelumab (82.3%). Of the 17.7% of TEAEs considered treatment-related, injection-site reactions, headache, fatigue, and asthenia occurred in &gt; 1 patient. Before lanadelumab initiation, most patients reported moderate-to-large HRQoL impairments; clinically meaningful improvements were observed 1 month after lanadelumab initiation and sustained throughout the study.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>Real-world data from ENABLE demonstrated long-term effectiveness of lanadelumab in patients with HAE aged ≥ 12 years and a safety profile consistent with previous clinical studies.</p>\u0000 </section>\u0000 </div>","PeriodicalId":10334,"journal":{"name":"Clinical and Translational Allergy","volume":"16 8","pages":""},"PeriodicalIF":4.2,"publicationDate":"2026-08-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13447952/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148683695","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Integrated Immune, Epithelial and Lipid Pathways in NSAID-Exacerbated Respiratory Disease","authors":"Piotr Szatkowski,&nbsp;Lucyna Mastalerz","doi":"10.1002/clt2.70182","DOIUrl":"10.1002/clt2.70182","url":null,"abstract":"<p>NSAID-exacerbated respiratory disease (N-ERD) is a chronic inflammatory disorder characterized by asthma, chronic rhinosinusitis with nasal polyps and respiratory reactions to cyclooxygenase-1 inhibiting nonsteroidal anti-inflammatory drugs (NSAID). Its pathogenesis involves dysregulated arachidonic acid metabolism, epithelial barrier dysfunction and activation of multiple immune cell types, including eosinophils, mast cells, macrophages, basophils, and innate lymphoid cells. Recent genomic and transcriptomic analyses have revealed variants in genes linked to epithelial integrity and cellular interactions, metabolic and epigenetic reprogramming of monocyte-derived macrophages that promotes persistent proinflammatory activity. Emerging biomarkers, such as 15-oxo-eicosatetraenoic acid (15-oxo-ETE), acylcarnitines, apolipoprotein E, oncostatin M, surfactant protein D, retinoic acid and glial cell line-derived neurotrophic factor provide novel mechanistic insights. A recently proposed Aspirin Hypersensitivity Diagnostic Index, integrating urinary leukotriene E4 (LTE4) and 15-oxo-ETE with sinus computed tomography (CT) scoring, may offer a practical noninvasive diagnostic tool. Inflammatory endotyping highlights substantial heterogeneity in N-ERD, encompassing T2-dominant, T1-, T3-related and neutrophilic inflammatory patterns, which may coexist or vary across airway compartments and influence clinical presentation and treatment response. As therapeutic strategies evolve, biologic agents targeting T2 pathways are becoming increasingly central, while aspirin therapy after desensitization may be reserved for selected patients. This review aims to summarize current mechanistic insights into the immune, epithelial, and lipid pathways involved in N-ERD, with a particular focus on emerging biomarkers and inflammatory endotypes relevant to diagnosis and personalized therapy.</p>","PeriodicalId":10334,"journal":{"name":"Clinical and Translational Allergy","volume":"16 8","pages":""},"PeriodicalIF":4.2,"publicationDate":"2026-08-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13431871/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148668597","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Criteria for Control and Remission of Respiratory Allergic Disease With Allergen Immunotherapy: A Delphi Consensus","authors":"Eloína González-Mancebo,&nbsp;Juan María Beitia Mazuecos,&nbsp;Ana I Tabar Purroy,&nbsp;Mar Gandolfo-Cano,&nbsp;Adriana Izquierdo-Domínguez,&nbsp;María José Castillo Marchuet,&nbsp;Cristina Cuevas Bravo,&nbsp;Leticia Domínguez Cereijo,&nbsp;Alicia Enríquez-Matas,&nbsp;Ignacio Esteban Gorgojo,&nbsp;Adrián Germán Sánchez,&nbsp;Alba Juárez Guerrero","doi":"10.1002/clt2.70191","DOIUrl":"10.1002/clt2.70191","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Allergic rhinitis, conjunctivitis and asthma are prevalent IgE-mediated respiratory diseases that frequently coexist and impair quality of life. Allergen immunotherapy (AIT) has clinical benefits and potential disease-modifying effects. Until recently, standardised definitions of disease control and remission were lacking in routine clinical practice, particularly for allergic rhinitis and conjunctivitis. This study aimed to propose preliminary definitions of control and remission in patients receiving AIT and to assess expert consensus using the Delphi methodology.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>A scientific committee developed a survey based on a literature review and expert input, addressing symptoms, medication use, quality of life, exacerbations and tools for objective and subjective assessment. Forty allergists participated in a two-round Delphi study. Consensus was predefined as ≥ 70% agreement on a 9-point Likert scale.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Consensus was achieved for all items after two rounds. The panel agreed on proposed definitions of disease control and clinical remission for allergic rhinitis, conjunctivitis and asthma in the context of AIT, integrating symptom severity, medication use, validated questionnaires and objective measures.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>This study presents preliminary expert-consensus definitions of control and remission in allergic rhinitis, conjunctivitis and asthma in patients undergoing AIT. These definitions should not be interpreted as validated clinical criteria or endpoints. As a preliminary proposal, they aim to provide a structured approach for assessing treatment response in clinical practice by integrating symptom burden, medication use, patient-reported outcomes and objective measures. They should be regarded as an initial conceptual step, and further prospective studies are needed to validate these criteria and confirm their relevance, feasibility and applicability.</p>\u0000 </section>\u0000 </div>","PeriodicalId":10334,"journal":{"name":"Clinical and Translational Allergy","volume":"16 8","pages":""},"PeriodicalIF":4.2,"publicationDate":"2026-08-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13429802/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148663606","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}